Vaccines-2013 - OMICS Group

Recommendations

Info

Jia-hui Lei et al., J Vaccines Vaccin 2013, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0173 rd International Conference onVaccines & VaccinationJuly 29-31, 2013 Embassy Suites Las Vegas, NV, USAEffect of Trichinella spiralis infection on the immune response to HBV vaccine in a mouse modelJia-hui Lei, Fei Guan, Xiao Hou, Wangfang Jiang and Wen-qi LiuDepartment of Parasitology, Tongji Medical College, Huazhong University of Science and Technology, P. R. ChinaVaccination is the most effective and cost-saving way to hepatitis B virus (HBV) infection. Collective data suggest that helminthinfections affect immune responses to some vaccines. Therefore it is important to reveal the effects of helminth infectionson protective vaccines efficacy in countries with highly prevalent helminth infections. In the present work, effects of Trichinellaspiralis infection on the protective efficacy of HBV vaccine in a mouse model were investigated. This study demonstrated thatthe enteric stage of T. spiralis infection could inhibit the proliferative response of spleen lymphocytes to hepatitis surface antigen(HBsAg) and lead to lower levels of anti-HBsAg antibodies, IFN-γ and IL-2, along with higher levels of IL-4 and IL-5. However,these immunological differences are absent in the muscle stage of T. spiralis infection. The results suggest that the muscle stage ofT. spiralis infection does not affect the immune response to HBV vaccination, while the enteric stage infection results in a reducedimmune response to HBsAg.Keywords: Trichinella spiralis; protective efficacy; hepatitis B; vaccineleijiahui@ hust.edu.cnJ Vaccines Vaccin 2013ISSN: 2157-7560, JVV an open access journalVaccines-2013July 29-31, 2013Volume 4 Issue 5Page 110
Byung Chul Kim et al., J Vaccines Vaccin 2013, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0173 rd International Conference onVaccines & VaccinationJuly 29-31, 2013 Embassy Suites Las Vegas, NV, USAEstablishment of the 3 rd national standard for in vitro potency assay of Japanese encephalitisvirus vaccineByung Chul Kim, Hyung-sil Moon, DoKeun Kim, Tae Moo Yoo, Sung Hwa Hong, Naery Lee, Jong-Mi Lim, Donghee Kim, Seokkee Chang,Jiyoung Hong, Jooyeon Lee and Ho Jung OhNational Institute of Food and Drug Safety Evaluation, KoreaTraditionally, the quality control for Japanese Encephalitis Virus (JEV) vaccine has performed in vivo potency assay usinganimals. The Ministry of Food and Drug Safety (MFDS) established alternative in vitro assay (ELISA) replacing the in vivoassay requiring animals and many times as an official quality control method of potency test for the JEV vaccine. The in vitropotency assay showed it's faster and easy to perform without pre-treatment such as a mouse immunization. Also it had betterprecision and reproducibility comparing to the conventional in vivo assay.The reference material is essential in order to evaluate potency test for the JEV vaccine. The 1 st and 2 nd national standardfor in vivo potency assay of JEV vaccine had manufactured, each established in 2001 and 2007, and have been using for themanufacturer's quality control and national lot release since then. As the need of the national standard for in vitro potency assay,this study was initiated by MFDS in 2013 to manufacture and establish the 3 rd national standard for in vitro and in vivo potencyassay of JEV vaccine. The in vitro and in vivo potency results of the candidate material for 3 rd national standard, each weremeasured 1.077 and 2.761. In the study hereafter, the collaborative study of the MFDS and manufacturers will be conducted toestimate the reliable virus content with the candidate material.happysea@korea.krJ Vaccines Vaccin 2013ISSN: 2157-7560, JVV an open access journalVaccines-2013July 29-31, 2013Volume 4 Issue 5Page 111
Page 1 and 2:
111 th OMICS Group ConferenceJuly 2
Page 3 and 4:
Medical SciencesISSNAddiction Resea
Page 5 and 6:
Impact Factors (IF) and Index Coper
Page 7 and 8:
111 th OMICS Group Conference3 rd I
Page 9 and 10:
Journal of Clinical & Cellular Immu
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Clinical Microbiology-2013OMICS Gro
Page 17 and 18:
Immunology Summit-2013OMICS Group i
Page 19 and 20:
Probiotics-2013OMICS Group is organ
Page 21 and 22:
Virology-2013OMICS Group is organiz
Page 23 and 24:
Page 25 and 26:
Because of heightened awareness of
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Ara Hovanessian, J Vaccines Vaccin
Page 35 and 36:
Nikolai Petrovsky, J Vaccines Vacci
Page 37 and 38:
Page 39 and 40:
Robert E. Sievers et al., J Vaccine
Page 41 and 42:
Xiao-Qing Wei, J Vaccines Vaccin 20
Page 43 and 44:
Campbell Bunce, J Vaccines Vaccin 2
Page 45 and 46:
Hong Xin, J Vaccines Vaccin 2013, 4
Page 47 and 48:
Diane Longo et al., J Vaccines Vacc
Page 49 and 50:
Track 33: Novel Approaches in Desig
Page 51 and 52:
Takashi Kei Kishimoto, J Vaccines V
Page 53 and 54:
Benjamin Petsch, J Vaccines Vaccin
Page 55 and 56:
A. Bennett Jenson et al., J Vaccine
Page 57 and 58:
Milan Raska et al., J Vaccines Vacc
Page 59 and 60: Muhammad Ali A. Shah et al., J Vacc
Page 61 and 62: Track 44: Vaccines against Infectio
Page 63 and 64: Haval Shirwan, J Vaccines Vaccin 20
Page 65 and 66: Rainer Fischer, J Vaccines Vaccin 2
Page 67 and 68: Alwyn Rapose, J Vaccines Vaccin 201
Page 69 and 70: Saroj Basak, J Vaccines Vaccin 2013
Page 71 and 72: Gisela Gonzalez, J Vaccines Vaccin
Page 73 and 74: Young Research ForumSession ChairPe
Page 75 and 76: Humberto Hernandez et al., J Vaccin
Page 77 and 78: Nisha Nair et al., J Vaccines Vacci
Page 79 and 80: Leow Yee et al., J Vaccines Vaccin
Page 81 and 82: Kaissar Tabynov et al., J Vaccines
Page 83 and 84: Teena Mohan et al., J Vaccines Vacc
Page 85 and 86: Track 5 & 95: Manufacturing, Produc
Page 87 and 88: Graham Clarke, J Vaccines Vaccin 20
Page 89 and 90: Obradovic Zarema et al., J Vaccines
Page 91 and 92: Abdur Razzaque Sarker et al., J Vac
Page 93 and 94: Omer Qutaiba B. Al-lela et al., J V
Page 95 and 96: 111 th OMICS Group Conference3 rd I
Page 97 and 98: Regina Heidenreich et al., J Vaccin
Page 99 and 100: Leow Y et al., J Vaccines Vaccin 20
Page 101 and 102: Zafer Kurugol et al., J Vaccines Va
Page 103 and 104: Ates Kara et al., J Vaccines Vaccin
Page 105 and 106: Yurong Tan et al., J Vaccines Vacci
Page 107 and 108: Deryabin P.N. et al., J Vaccines Va
Page 109: Xiao-Yong Fan et al., J Vaccines Va
Page 113 and 114: STS. Chitradevi et al., J Vaccines
Page 115 and 116: Yan Liang et al., J Vaccines Vaccin
Page 119 and 120: Afshineh Latifynia et al., J Vaccin
Page 121 and 122: Hemanta Koley et al., J Vaccines Va
Page 123 and 124: Aleksandar Masic et al., J Vaccines
Page 125 and 126: Hassen Mamo, J Vaccines Vaccin 2013
Page 127 and 128: Oladipo Aina et al., J Vaccines Vac
Page 129 and 130: Aiswariya Chidambaram, J Vaccines V
Page 131 and 132: Birhanu Hurisa et al., J Vaccines V
Page 133 and 134: Ghaffarifar F et al., J Vaccines Va
Page 135 and 136: Mathan Periasamy et al., J Vaccines
Page 137 and 138: Rania Abdel Hay, J Vaccines Vaccin
Page 139 and 140: Samuel Teshome, J Vaccines Vaccin 2
Page 143 and 144: Birhanu Hurisa et al., J Vaccines V
Page 145 and 146: Dhrubajyoti Nag, J Vaccines Vaccin
Page 147 and 148: Belachew Etana et al., J Vaccines V
Page 149 and 150: Fatemeh Ghaffarifar et al., J Vacci
Page 151 and 152: Moustafa A.F. Abbas et al., J Vacci
Page 153 and 154: Prerna Chaudhary, J Vaccines Vaccin
Page 155 and 156: Sandeepkumar R. Chauhan et al., J V
Page 157 and 158: Veronica Rainone et al., J Vaccines
Page 159 and 160: Page 159
Page 161 and 162:
Previous111 th OMICS Group Conferen
Page 163 and 164:
PreviousWorld Congress and Expo onB
show all

Vaccines-2013 - OMICS Group

Create successful ePaper yourself

Delete template?

Save as template?